As VSV-GP is an oncolytic agent developed for potential cancer therapies, we included the newly identified epitopes to comprehensively monitor VSV-GP-specific CD8+ T cells in virotherapy settings in tumor-bearing mice. This evidence concerns the gene CD8A and cancer.